Safety and efficacy of alcohol septal ablation in adolescents and young adults with hypertrophic obstructive cardiomyopathy.
Adolescents
Alcohol septal ablation
Hypertrophic obstructive cardiomyopathy
Outcome
Young adults
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
29
07
2021
accepted:
21
10
2021
pubmed:
25
11
2021
medline:
22
2
2022
entrez:
24
11
2021
Statut:
ppublish
Résumé
Data regarding alcohol septal ablation (ASA) in young patients with hypertrophic obstructive cardiomyopathy (HOCM) are scarce. The purpose of our study is to evaluate the safety and efficacy of ASA in patients ≤ 25 years. All ASAs between 2002 and 2020 at our institution were assigned to a group of patients 14-25 years of age (group 1) and a reference group > 25 years (group 2). 1,264 procedures were analysed in group 2 (58.6 ± 13.5 years) and 41 procedures in group 1 (20.9 ± 3.3 years). The baseline interventricular septal diameter (IVSD) was higher in group 1 (26.0 ± 6.5 mm vs. 21.3 ± 4.4 mm; p < 0.0001). There was no difference in baseline left ventricular outflow tract gradient (LVOTG) (group 1: 54.4 ± 24.4 mmHg; group 2: 52.4 ± 36.6 mmHg; p = n.s.). A previous cardiac device was more often observed in group 1 (31.7% vs. 9.0%; p < 0.0001). Symptoms were improved after 6 months (group 1: mean NYHA class 2.5 at baseline and 1.3 at FU; p < 0.0001; group 2: mean NYHA class 2.7 at baseline and 1.4 at FU; p <0 .0001). IVSD (group 1: 20.3 ± 8.2 mm; group 2: 16.8 ± 5.7 mm; p < 0.0001 for each group compared to baseline) and LVOTG improved during FU (group 1: 25.5 ± 20.0 mmHg; group 2: 22.1 ± 21.7 mmHg; p < 0.0001 for each group). Intrahospital mortality was 0.0% in patients 14-25 years and 0.9% in the reference group. Persistent AV-block was observed in 12.2% of the group 1 and 15.9% of the group 2 patients (p = n.s.). ASA is safe and effective in HOCM patients 14-25 years of age in experienced centres.
Identifiants
pubmed: 34817646
doi: 10.1007/s00392-021-01960-6
pii: 10.1007/s00392-021-01960-6
doi:
Substances chimiques
Ethanol
3K9958V90M
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-217Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Maron BJ, Gardin JM, Flack JM et al (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785–789. https://doi.org/10.1161/01.cir.92.4.785
doi: 10.1161/01.cir.92.4.785
pubmed: 7641357
Maron MS, Olivotto I, Betocchi S et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295–303. https://doi.org/10.1056/NEJMoa021332
doi: 10.1056/NEJMoa021332
pubmed: 12540642
Elliott PM, Anastasakis A et al (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779. https://doi.org/10.1093/eurheartj/ehu284
doi: 10.1093/eurheartj/ehu284
pubmed: 25173338
Morrow AG, Reitz BA, Epstein SE et al (1975) Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 52:88–102. https://doi.org/10.1161/01.cir.52.1.88
doi: 10.1161/01.cir.52.1.88
pubmed: 1169134
Kuhn H, Gietzen F, Leuner C, Gerenkamp T (1997) Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846–851
doi: 10.1093/oxfordjournals.eurheartj.a015350
Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214. https://doi.org/10.1016/s0140-6736(95)91267-3
doi: 10.1016/s0140-6736(95)91267-3
pubmed: 7616800
Agarwal S, Tuzcu EM, Desai MY et al (2010) Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol 55:823–834. https://doi.org/10.1016/j.jacc.2009.09.047
doi: 10.1016/j.jacc.2009.09.047
pubmed: 20170823
Leonardi RA, Kransdorf EP, Simel DL, Wang A (2010) Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv 3:97–104. https://doi.org/10.1161/CIRCINTERVENTIONS.109.916676
doi: 10.1161/CIRCINTERVENTIONS.109.916676
pubmed: 20197511
Osman M, Kheiri B, Osman K et al (2019) Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis. Clin Cardiol 42:190–197. https://doi.org/10.1002/clc.23113
doi: 10.1002/clc.23113
pubmed: 30421437
Lipshultz SE, Sleeper LA, Towbin JA et al (2003) The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348:1647–1655. https://doi.org/10.1056/NEJMoa021715
doi: 10.1056/NEJMoa021715
pubmed: 12711739
Seggewiss H, Rigopoulos A (2003) Management of hypertrophic cardiomyopathy in children. Paediatr Drugs 5:663–672. https://doi.org/10.2165/00148581-200305100-00002
doi: 10.2165/00148581-200305100-00002
pubmed: 14510624
Pacileo G, De Cristofaro M, Russo MG et al (2000) Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function. Can J Cardiol 16:146–152
pubmed: 10694584
Georgakopoulos D, Tolis V (2007) Hypertrophic cardiomyopathy in children, teenagers and young adults. Hellenic J Cardiol 48:228–233
pubmed: 17715614
Ommen SR, Mital S et al (2020) 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. https://doi.org/10.1161/CIR.0000000000000937
doi: 10.1161/CIR.0000000000000937
pubmed: 33215938
Zhu C, Wang S, Ma Y et al (2019) Childhood hypertrophic obstructive cardiomyopathy and its relevant surgical outcome. Ann Thorac Surg. https://doi.org/10.1016/j.athoracsur.2019.10.016
doi: 10.1016/j.athoracsur.2019.10.016
pubmed: 31891696
Xu H, Yan J, Wang Q et al (2016) Extended septal myectomy for hypertrophic obstructive cardiomyopathy in children and adolescents. Pediatr Cardiol 37:1091–1097. https://doi.org/10.1007/s00246-016-1396-5
doi: 10.1007/s00246-016-1396-5
pubmed: 27160105
Theodoro DA, Danielson GK, Feldt RH, Anderson BJ (1996) Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. J Thorac Cardiovasc Surg 112:1589–1597. https://doi.org/10.1016/S0022-5223(96)70018-1 (discussion 1597–1599)
doi: 10.1016/S0022-5223(96)70018-1
pubmed: 8975851
Minakata K, Dearani JA, O’Leary PW, Danielson GK (2005) Septal myectomy for obstructive hypertrophic cardiomyopathy in pediatric patients: early and late results. Ann Thorac Surg 80:1424–1429. https://doi.org/10.1016/j.athoracsur.2005.03.109 (discussion 1429–1430)
doi: 10.1016/j.athoracsur.2005.03.109
pubmed: 16181882
Delmo Walter EMB, Siniawski H, Hetzer R (2009) Sustained improvement after combined anterior mitral valve leaflet retention plasty and septal myectomy in preventing systolic anterior motion in hypertrophic obstructive cardiomyopathy in children. Eur J Cardiothorac Surg 36:546–552. https://doi.org/10.1016/j.ejcts.2009.03.049
doi: 10.1016/j.ejcts.2009.03.049
pubmed: 19464922
Altarabsheh SE, Dearani JA, Burkhart HM et al (2013) Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults. Ann Thorac Surg 95:663–669. https://doi.org/10.1016/j.athoracsur.2012.08.011 (discussion 669)
doi: 10.1016/j.athoracsur.2012.08.011
pubmed: 23040828
Abbey S, Guérin P, Gournay V et al (2005) Septal alcoholisation of hypertrophic obstructive cardiomyopathy in childhood. Arch Mal Coeur Vaiss 98:574–578
pubmed: 15966612
Cano MN, Fortunato de Cano SJ, Sousa JEMR (2010) Alcohol septal ablation after myomectomy failure solutions for unusual cases. Catheter Cardiovasc Interv 76:719–723. https://doi.org/10.1002/ccd.22539
doi: 10.1002/ccd.22539
pubmed: 20799353
Emmel M, Sreeram N (2005) Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in children. Neth Heart J 13:448–451
pubmed: 25696442
pmcid: 2497374
Sreeram N, Emmel M, de Giovanni JV (2011) Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children. J Am Coll Cardiol 58:2501–2510. https://doi.org/10.1016/j.jacc.2011.09.020
doi: 10.1016/j.jacc.2011.09.020
pubmed: 22133850
Subash Chandra V, Jayranganth M, Shenoy AR (2006) Non-surgical septal reduction for hypertrophic cardiomyopathy in childhood. Int J Cardiol 106:355–359. https://doi.org/10.1016/j.ijcard.2005.02.009
doi: 10.1016/j.ijcard.2005.02.009
pubmed: 16337044
Zhang X, Li Y, Xie B et al (2011) Non-drug treatment for hypertrophic obstructive cardiomyopathy in children. Zhonghua Er Ke Za Zhi 49:381–385
pubmed: 21624293
Hickey EJ, McCrindle BW, Larsen S-H et al (2012) Hypertrophic cardiomyopathy in childhood: disease natural history, impact of obstruction, and its influence on survival. Ann Thorac Surg 93:840–848. https://doi.org/10.1016/j.athoracsur.2011.10.032
doi: 10.1016/j.athoracsur.2011.10.032
pubmed: 22284306
Lawrenz T, Lieder F, Bartelsmeier M et al (2007) Predictors of complete heart block after transcoronary ablation of septal hypertrophy. J Am Coll Cardiol 49:2356–2363. https://doi.org/10.1016/j.jacc.2007.02.056
doi: 10.1016/j.jacc.2007.02.056
pubmed: 17572252
Nagueh SF, Groves BM, Schwartz L et al (2011) Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol 58:2322–2328. https://doi.org/10.1016/j.jacc.2011.06.073
doi: 10.1016/j.jacc.2011.06.073
pubmed: 22093510
Gietzen FH, Leuner CJ, Raute-Kreinsen U et al (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342–1354. https://doi.org/10.1053/euhj.1999.1520
doi: 10.1053/euhj.1999.1520
pubmed: 10462469
Liebregts M, Faber L, Jensen MK et al (2017) Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv 10:1134–1143. https://doi.org/10.1016/j.jcin.2017.03.030
doi: 10.1016/j.jcin.2017.03.030
pubmed: 28595881
An S, Yang Y, Hang F et al (2017) Procedural complication and long term outcomes after alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: data from China. Sci Rep 7:9506. https://doi.org/10.1038/s41598-017-10144-0
doi: 10.1038/s41598-017-10144-0
pubmed: 28842653
pmcid: 5572739
Rangavajla G, Mulukutla S, Thoma F et al (2021) Ventricular pacing and myocardial function in patient with congenital heart block. J Cardiovasc Electrophysiol. https://doi.org/10.1111/jce.15207
doi: 10.1111/jce.15207
pubmed: 34409682
Galve E, Sambola A, Saldaña G et al (2010) Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart 96:352–356. https://doi.org/10.1136/hrt.2008.158915
doi: 10.1136/hrt.2008.158915
pubmed: 19482844
Lucon A, Palud L, Pavin D et al (2013) Very late effects of dual chamber pacing therapy for obstructive hypertrophic cardiomyopathy. Arch Cardiovasc Dis 106:373–381. https://doi.org/10.1016/j.acvd.2013.04.003
doi: 10.1016/j.acvd.2013.04.003
pubmed: 23806305
Megevand A, Ingles J, Richmond DR, Semsarian C (2005) Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. Am J Cardiol 95:991–993. https://doi.org/10.1016/j.amjcard.2004.12.045
doi: 10.1016/j.amjcard.2004.12.045
pubmed: 15820173
Slade AK, Sadoul N, Shapiro L et al (1996) DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart 75:44–49. https://doi.org/10.1136/hrt.75.1.44
doi: 10.1136/hrt.75.1.44
pubmed: 8624871
pmcid: 484221
Kim LK, Swaminathan RV, Looser P et al (2016) Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003–2011. JAMA Cardiol 1:324–332. https://doi.org/10.1001/jamacardio.2016.0252
doi: 10.1001/jamacardio.2016.0252
pubmed: 27438114